One of the first things many people notice on a GLP-1 medication has nothing to do with the number on the scale. It is a kind of silence. The constant background hum of thoughts about food, what to eat next, the snack you were half-planning, the pull of the cupboard at 9pm, simply goes quiet. People describe it as startling, and mostly as a relief. The phrase that has stuck is “food noise,” and its quieting is, for a lot of people, the single most freeing part of the experience.
But there is a second thing some people notice, and almost no one is warned about it. The quiet does not always stay confined to food. For a subset of people, it spreads. The glass of wine that used to round off the day feels like less of an event. The meal out with friends is pleasant but somehow flatter. The things you used to look forward to, the shared dinner, the Friday drinks, the bit of the week that had a bit of sparkle on it, arrive slightly dimmed. If that is happening to you, you are not imagining it, you are not ungrateful, and you are not broken. There is a plausible reason for it, and it is worth understanding rather than worrying about in silence.
What “food noise” actually is, and why it goes quiet
Food noise is not a clinical term, but it describes something real: the intrusive, recurring mental preoccupation with food that many people with a history of weight struggle live with constantly. GLP-1 medications act not only on the gut but on the brain’s reward circuitry, the system that assigns a sense of “I want that” to things, including food. By turning down the volume on that wanting, the medication quiets the preoccupation. The food stops shouting.
This is a genuine and valuable effect. For people who have spent years with food as a loud, demanding presence, the silence can feel like getting a part of their mind back. That is worth saying clearly, because the rest of this piece is about a complication of the same mechanism, and the complication does not cancel out the benefit.
When the quiet spreads
Here is the part that needs naming. The brain’s reward system is not neatly divided into a “food” section and an “everything else” section. The circuitry that the medication alters, centred on a region called the ventral tegmental area and the dopamine signalling it drives, is the same circuitry that assigns anticipation and pleasure to a great many things, not just eating. (One 2023 study found that semaglutide actually increased VTA dopamine response during palatable food consumption, suggesting the mechanism involves altering rather than simply suppressing reward signalling — a distinction that matters for understanding the range of effects people describe.) So when the medication quiets the wanting, it can, in some people, quiet more than food.
The patient reports describing this have grown over the last couple of years, and they cluster around a few themes. A general flattening of motivation, a sense that the things that used to generate a pull, a bit of drive, a bit of looking-forward-to, generate less of it. Reduced interest in alcohol, which for some is a welcome side benefit and for others is the quiet loss of a way they used to unwind or connect. A dimming of anticipation more broadly, where rewards that used to feel like rewards feel more neutral.
It is worth being precise about what this is and is not, because the distinction matters enormously. This is not the same as the medication causing depression, and conflating the two would be both inaccurate and unhelpful. We will come back to that distinction directly, because it is important. What patients are describing is closer to a turning-down of the reward and anticipation system, the same system the drug is designed to act on, sometimes reaching further than the food it was aimed at.
The part that often hurts most: the social cost
Of all the places this can show up, the one that seems to matter most to people, and the one least talked about, is social.
So much of how we connect with the people we love is built around shared reward. The family dinner. The meal on a date. The drinks with colleagues that turn coworkers into friends. The Sunday lunch, the celebration, the bottle of something good opened for an occasion. These are not just about food and alcohol; they are the scaffolding of belonging. They are how we mark that something matters, and how we spend unhurried time with the people we care about.
When the pull toward those things dims, the effect is not only personal, it is relational. The shared meal that used to be a highlight can become something you participate in rather than enjoy. The round of drinks you used to be part of, you sit out, and a small thread of connection thins. Some people notice it extends even to things like exercising with friends, the run or the gym session that was as much about the company as the activity, where the motivation that used to get you there has quietly softened. None of these are catastrophes on their own. But they accumulate, and the accumulation is a real reduction in the social texture of life, often felt before it is named, and easy to mistake for something being wrong with you rather than with a brain chemical that has been turned down a notch.
Naming it is the first relief. The flatness you feel at the dinner table is not a failure of love or gratitude. It is, plausibly, the same dial that quieted the food noise, reaching one table further than you wanted it to.
Is this depression? Almost certainly not, and the distinction matters
This is the point where it would be easy to frighten people, so it is worth being careful and accurate.
What is described above, the reward flattening, is not the same as the medication causing clinical depression, and the evidence on depression specifically is reassuring. Large analyses and trials have generally found GLP-1 medications associated with neutral to modestly positive effects on depressive symptoms, not negative ones, which is part of why regulators removed an earlier precautionary warning about mood. So the headline question, “will this drug make me depressed,” is, on the current evidence, answered no for the great majority of people.
The reward and motivation flattening is a different and more specific thing: a turning-down of anticipation and pleasure-seeking, plausibly tied to the same dopamine circuitry the drug acts on, and it is genuinely under-studied. No large trial has yet measured it properly with the right tools, which is an honest gap rather than a reassurance. So the accurate position is twofold. The drug is not, on present evidence, a cause of depression. And the reward-flattening some people describe is real, plausible, and deserves to be taken seriously rather than dismissed. Both of those are true at once.
There is one important caveat that does not let us off the hook. For a person who already lives with depression, or who has used food, alcohol or social reward as a way of managing low mood, a broad turning-down of the reward system could remove a coping mechanism they were quietly relying on, and that is worth watching. If you have a history of depression and you notice your mood, not just your motivation, sliding, that is a reason to talk to your GP or a mental health professional, not to push through. The distinction to hold is between interest and anticipation feeling dimmed (the reward effect) and mood, hope, sleep, and sense of worth declining (which points toward depression and warrants help). They can feel similar from the inside, which is exactly why a conversation with someone who can tell them apart is worth having.
Does it get better? What we can and can’t say yet
The question everyone asks is whether this fades the way the nausea fades, as the body adapts.
The truthful position is that we do not yet know with confidence, and anyone who tells you otherwise is ahead of the evidence. Some of the gut-level effects of these medications do attenuate over time as the body habituates. Whether the reward-flattening follows the same course, eases as you settle on a stable dose, or persists, has not been properly studied, and the patient reports are mixed. Some people describe it lifting after the early months or after a dose stabilises. Others describe it as steadier. Dose appears to matter for many people, with the effect more pronounced at higher doses, which is one of the levers worth knowing about.
What this means in practice is that it is reasonable to expect some settling, to give it time on a stable dose before concluding it is permanent, and at the same time not to simply endure a significant and persistent flattening on the assumption that it must eventually pass. It is a thing to monitor and discuss, not a verdict.
What to actually do about it
If you recognise yourself in this, there are real, practical responses, and they range from things you can do yourself to things worth raising with your prescriber.
Name it, to yourself and to the people close to you. A surprising amount of the harm here is the private confusion, the sense that you have gone flat and do not know why, and the worry that something is wrong with you. Telling a partner “the medication seems to have turned down how much I look forward to things, including our usual dinners, and it is the drug, not us” can defuse a tension that might otherwise quietly build.
Keep showing up to the shared occasions even when the pull is weaker. This is the counterintuitive one. When the internal motivation dims, the social ritual still delivers connection even if the anticipation is muted, and the connection is worth protecting on its own terms. Behaviour can lead and feeling can follow. Going to the dinner because it matters, rather than because you are pulled to it, keeps the relationships intact through the flat patch.
Shift what you anticipate towards things the medication does not dull. Reward that comes from mastery, accomplishment, connection, and meaning, finishing something, a good conversation, time outdoors, progress on something you care about, often survives better than the consumption-based rewards (food, alcohol) the drug most directly targets. Deliberately leaning into those can rebuild some of the texture.
Talk to your prescriber about dose. Because the effect appears dose-related for many people, a clinician may be able to adjust the dose or the titration to find the level where the food benefit holds but the broader flattening eases. This is a real lever and a legitimate reason to have the conversation, not a reason to silently tolerate it or to stop the medication on your own.
Watch the line between dimmed and depressed. As above, if what you are experiencing is shading from “less interested” into low mood, hopelessness, or withdrawal, treat that as a reason to seek proper support rather than something to manage alone.
The thing worth holding onto
The quieting of food noise is, for most people, one of the best things these medications do. The point of naming its further-reaching cousin is not to scare anyone off, it is the opposite. A vague, unsettling flatness that you cannot explain is far harder to live with than a named, understood effect that you can talk about, monitor, and work with. Most people will not experience the broader flattening at all. Some will, mildly and briefly. A few will find it significant enough to act on. All of them are better served by knowing it is a recognised possibility, tied to a real mechanism, than by quietly wondering what happened to the part of them that used to look forward to dinner.
If that is you, it is worth a conversation, at Anova or with your own GP, rather than a worry carried alone. It has a name, it has a plausible cause, and it has things you can do about it.
This is a sensitive area. If you are noticing changes in your mood rather than just your motivation, or if any of this resonates in a way that feels heavier than a dimming of interest, please reach out to your GP or a mental health professional. If you would like, we can help you find the right support.